(Invested Since 2009)

Genscript Holdings (Cayman) Limited

GenScript is the largest and fastest growing biology Contract Research Organization (CRO) in China, focusing exclusively on early drug development services. It uses an assembly-line mode to provide a one-stop solution to pharmaceutical companies, biotech companies, and research institutions—including Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development. Genscript’s high growth is based on its first mover advantage, high barriers to entry, China’s large talent pool of science and engineering students, and the growing demand to outsource pre-clinical drug development for time efficiency and cost effectiveness. Genscript is the most cited biology CRO in the world. More than 9,000 papers cite the service and products from GenScript as the largest gene synthesis capacity in the world with over 100 million bp/month — a record length fifty kb — with turnaround time as short as four business days.

On February 26, 2015, GenScript announced that they have entered into a non-exclusive license agreement with the Broad Institute of MIT and Harvard to strengthen their existing GenCRISPR™ services portfolio with the set of extensive intellectual properties and technologies related to CRISPR/Cas9 genome editing systems from the Broad Institute.